According to Mark K. Buyyounouski, MD, and coauthors, “[Hypofractionated postprostatectomy radiotherapy] is a new acceptable practice standard for patients receiving postprostatectomy radiotherapy.” Learn more: hmpgloballearningnetwork.com/site/onc/news/…

#medtwitter #onctwitter

At the 2024 Great Debates & Updates #GDUHem meeting, Jessica Altman, MD, Northwestern Medicine, argues in favor of using sequential therapy over triplet therapy for patients with newly diagnosed #AML who are ineligible for intensive chemo. Learn more: hmpgloballearningnetwork.com/site/onc/confe… Jessica Altman, MD

In this video, Andrew Katims, MD MPH discusses challenges associated with treating patients with high-risk non-muscle invasive bladder cancer during the bacillus Calmette-Guerin shortage. Learn more: hmpgloballearningnetwork.com/site/onc/video…

#medtwitter #onctwitter

At the 2024 Great Debates & Updates #GDUHem meeting, Andrew Yee, MD, Mass General Cancer Center, Harvard Medical School, discussed whether or not it is suitable for a patient to receive additional #BCMA therapy after previous BCMA therapy. Learn more: hmpgloballearningnetwork.com/site/onc/confe… Andrew Yee, MD #OncTwitter

Unlock the latest insights in chronic lymphocytic leukemia (CLL) treatment with our informative video on 5-year off-treatment analyses. Discover findings from 2 pivotal trials. Learn more: hmpgloballearningnetwork.com/site/onc-app/u…

#ChronicLymphocyticLeukemia #MedicalResearch #ProviderLearning

At the Great Debates & Updates in Hematologic Malignancies meeting in New York, Jia Ruan, MD, PhD, Weill Cornell Medicine, shares various active evaluations and topics of interest within the #MCL treatment landscape. Learn more: hmpgloballearningnetwork.com/site/llm/confe… #OncTwitter #GDU Hem #GDU #MedTwitter

According to Erica Mayer 'continuation of the same CDK4/6i beyond progression in combination with a change from [an aromatase inhibitor] to fulvestrant does not yield a PFS benefit compared with fulvestrant alone.' Learn more: hmpgloballearningnetwork.com/site/onc/news/…

#medtwitter #onctwitter

At the 2024 Great Debates & Updates ( #GDU ) in Hematological Malignancies meeting, WCM Englander Institute for Precision Medicine's Dr. Peter Martin (@WCMLymphoma), argued in favor of alternative treatment regimens over CAR T-cell therapy for follicular #lymphoma . #PrecisionMedicine

hmpgloballearningnetwork.com/site/onc/confe…

At the 2024 Great Debates & Updates #GDU in Hematological Malignancies meeting, Peter Martin, MD, Weill Cornell Medicine, argued in favor of alternative treatment regimens over CAR T-cell therapy for #FollicularLymphoma , highlighting 3 managements. Learn more: hmpgloballearningnetwork.com/site/onc/confe… #Oncology

The U.S. FDA granted accelerated approval to trastuzumab deruxtecan for patients with unresectable or metastatic HER2-positive solid tumors. Learn more: hmpgloballearningnetwork.com/site/onc/news/…

#medtwitter #onctwitter #FDAapprovals

At the 2024 Great Debates & Updates #GDU in Hematologic Malignancies meeting, Samuel Yamshon, MD, Weill Cornell Medicine, examines the efficacy of using CAR T-cell therapy to treat elderly patients with R/R #DLBCL . Learn more: hmpgloballearningnetwork.com/site/onc/confe… Sam Yamshon #Oncology #OncTwitter #GDU Hem

At the 2024 Great Debates & Updates #GDU in Hematologic Malignancies meeting, Joshua Richter, MD, FACP, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, explores the role of MRD in multiple myeloma treatment, addressing whether it should be used to make clinical decisions. Learn more: hmpgloballearningnetwork.com/site/onc/confe…

🎥 Behind-the-scenes at #GDUHEM at the Westin Times Square. Join us tomorrow to hear what the leading experts have to say & delve into the cutting-edge advances in the treatment of blood cancer. ➡️hmpglobalevents.com/gduhem

#greatdebatesandupdates Jessica Altman, MD Aditi Shastri, MD

At the 2024 Great Debates & Updates Great Debates and Updates Meeting in Hematological Malignancies in New York, John Allan, MD, Weill Cornell Medicine, discusses if there is a role for chemo-immunotherapy in the #CLL treatment landscape. Learn more: hmpgloballearningnetwork.com/site/llm/confe… Lymphoma, Leukemia & Myeloma Congress #GDUHem

According to Matthew M Lei, PharmD, Mass General Cancer Center, and colleagues, “This retrospective cohort study demonstrated that [venetoclax-obinutuzumab] achieves frequent, durable responses and can be safely administered in [R/R] CLL/SLL.” Learn more:hmpgloballearningnetwork.com/site/onc/news/… Matthew Lei

.Elias K. Mai MD, MD, Heidelberg Myeloma, and coauthors concluded that the phase 3 trial results on this addition 'did not improve survival outcomes in patients with newly diagnosed #MultipleMyeloma who are eligible for an autologous HSCT.” Learn more: hmpgloballearningnetwork.com/site/onc/news/… #MedTwitter

At the #SGOmtg , Aine Clements, MD, discussed ancillary results from the phase 3 GOG-0258 trial. Learn more: hmpgloballearningnetwork.com/site/onc/confe…

#medtwitter #onctwitter

In this video, Jie Jin, MD, PhD, Zhejiang University, shares results from a phase 2 study assessing the efficacy of JAK inhibitor #jaktinib among #ruxolitinib -intolerant patients with #myelofibrosis . Learn more: hmpgloballearningnetwork.com/site/onc/video… #OncTwitter #MedTwitter #Oncology #Oncologist

Interim analysis results from the phase 3 RATIONALE-315 study demonstrated that neoadjuvant tislelizumab plus chemotherapy with adjuvant tislelizumab significantly improved the EFS/OS in stage II to IIIA NSCLC. Learn more: hmpgloballearningnetwork.com/site/onc/news/…

#medtwitter #onctwitter

Here, Benjamin Tomlinson, MD, University Hospitals, discusses the course of treatment he chose for a younger patient with a common presentation of myelodysplastic syndrome #MDS with isolated deletion of 5q. Learn more:hmpgloballearningnetwork.com/site/onc/video… #OncTwitter #MedTwitter #Oncology #Oncologist